Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.

V Di Lauro, G Barchiesi,F Martorana, G Zucchini, M Muratore,C Fontanella,G Arpino,L Del Mastro,M Giuliano, F Puglisi,M De Laurentiis

ESMO open（2022）

引用 5|浏览5

暂无评分

摘要

Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice.

查看译文

关键词

abemaciclib,cyclin-dependent 4/6 inhibitors,health-related quality of life,palbociclib,ribociclib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要